Name : Human SLAMF7/CRACC/CD319 Protein
Product Source :
Recombinant Human SLAMF7/CRACC/CD319 Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Ser23-Met226.[Accession | Q9NQ25-1]
Molecular Weight :
The protein has a predicted MW of 49.2 kDa. Due to glycosylation, the protein migrates to 68-80 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human SLAMF7 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human SLAMF7 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Human SLAMF7, hFc Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Anti-SLAMF7 Antibody, hFc Tag with the EC50 10.4ng/ml determined by ELISA.
Background :
CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family.Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response.
Synonyms :
CD2 subset 1; CRACC; Novel Ly9; CD319; SLAMF7; CS1; 19A; FOAP-12
References & Citations :
(1)Niels W. C. J. van de Donk, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma[J]. Blood, 2016, 127(6):681-695.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
14-3-3 theta ProteinSource
CELA2A Proteinweb
Popular categories:
PPAR-delta
Langerin